Brought to you by 
Symphony financing to support OxiGene cancer, eye programs
06 Oct 2008
Executive Summary
Private equity group Symphony Capital Partners has created and agreed to invest up to $25mm in Symphony Vida, an off-balance sheet entity that will take on the development risk of biotech OxiGene's ophthalmic program. As part of the deal, Symphony Capital may elect two members to OxiGene's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
- Special-Purpose Financing Vehicle
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Symphony financing to support OxiGene cancer, eye programs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice